Objective: Although commonly encountered, little work has defi ned the longitudinal course of treatment-resistant depression (TRD) and the infl uence of residual posttreatment symptoms on longer-term outcome. The aim of our study was to assess the impact of posttreatment clinical states on longer-term outcome.
S oon after the introduction of the fi rst ADs, it was recognized that a signifi cant proportion of patients treated with ADs fail to show satisfactory response. [1] [2] [3] [4] [5] [6] Now, 60 years later, after the deployment of numerous alternative ADs, TRD remains a major public health challenge. It is common [7] [8] [9] [10] and is associated with high levels of comorbidity, disability, and cost. [11] [12] [13] [14] [15] TRD remains underresearched: its etiology, pathophysiology, and course are poorly understood.
Unlike in less chronic and refractory forms of depression, where remission has been advocated as a potentially measurable and clinically meaningful treatment end point, 8, [16] [17] [18] no explicit treatment end point 17 has been suggested in TRD. The extent to which residual symptoms confer a poorer outcome in TRD is also unclear. In the context of chronic and refractory illness, residual symptoms might be expected, to some extent, and be less concerning than in more acute illnesses. Indeed, given the poor long-term prognosis in TRD, 19 it could be argued that a more realistic aim of treatment in TRD could be amelioration of symptoms and symptom management, rather than symptom remission or cure. Conversely, it may also be that TRD is essentially an extension of ordinary depressive disorder, and that residual symptoms will confer an adverse prognosis in the same way. If that is so, the explicit aim of treatment in TRD should also be for a full remission of symptoms. Our study assessed the use of posttreatment clinical states as potential treatment end points in TRD. We hypothesized that patients discharged still in episode, or only in partial remission rather than full remission, would have poorer longer-term outcomes than patients discharged in remission, in terms of clinical status, functioning, and quality of life outcomes measured, both longitudinally and cross-sectionally.
Method

Participants
The cohort consisted of patients with TRD who had received intensive inpatient treatment in a specialist unit for the treatment of complex mood disorders in the United Kingdom. Patients had received individualized treatment packages that consisted of pharmacotherapy (mostly using medication combinations), individual and couple psychological therapy, and other physical therapies as indicated. 20 Diagnosis and level of treatment resistance were established within the unit before discharge. Only patients who had failed to respond to at least one adequate dose of ADs were included in the study. Adequacy of treatment was defi ned according to the Maudsley Prescribing Guideline. 21 Clinical and demographic details are given in Table 1 .
Outcomes
Primary Outcome. A dichotomous summary outcome (good, compared with poor, outcome) was generated based on the available longitudinal data from the LIFE chart. 22 We considered that spending less time in remission than the median percentage time of remission of the whole follow-up cohort, and spending more time in episode than the median percentage time spent in episode by the whole cohort, would constitute a poor outcome. Conversely, we assumed that spending more time in remission than the cohort median and less time in episode than the cohort median would constitute a good outcome. As TRD is a longitudinal condition, summaries based on the longitudinal course were deemed more appropriate as primary outcomes than crosssectional follow-up measures.
Secondary Outcomes. The main secondary outcome was the clinical status of the cohort at end of follow-up; that is, whether patients were in full remission, in episode, or signifi cantly symptomatic without being in episode (subthreshold state). Being in full remission was rated when virtually no depressive symptoms were exhibited, irrespective of the state of comorbid symptoms or disorders, such as anxiety and obsessive-compulsive disorders. An episode was defi ned by the occurrence of depressive symptoms suffi cient to meet criteria for a depressive episode according to the ICD-10 criteria. 23 Additional secondary outcomes comprised longitudinal symptomatic state and cross-sectional severity of illness, determined using dimensional symptom scales, and functional and quality of life outcomes.
The study was approved by the local ethics committee, and participants gave informed consent for participation.
Assessment Instruments
Clinical Outcome. The LIFE chart was the main assessment tool used to establish longitudinal clinical outcome. This is a well-established follow-up evaluation scale that allows the weekly or monthly symptomatic state of a patient to be rated retrospectively at follow-up intervals of 6 months or longer. 22 Symptoms are rated on a 6-or 7-point scale (the latter a United Kingdom modifi cation), 24, 25 called the PSR, and linked with symptoms in the ICD-10. 23 In this study, the 7-point scale was used to record the monthly clinical status of patients for the interval between discharge and followup. The PSR scores range from an asymptomatic state (score of 1) to a severe episode with psychosis or severe impairment (score of 7). The cross-sectional symptomatic severity at the end of the follow-up was ascertained using the 17-item HDRS 26 and the QIDS-C, and self-rated QIDS versions. 27 The HDRS is the most widely used instrument in the study of treatment response in depression, 28 while the QIDS has been recently developed as an alternative with good psychometric properties. 27 Functional Outcome. We administered the GAF, 29 a widely used dimensional scale that allows rating of impairment in psychological, social, and occupational functioning. The GAF scores vary from 0 to 100.
Defi nition of Main Clinical States.
The main clinical states were determined using the LIFE chart. PSR scores of 1 to 2 were equated with remission, scores of 3 to 4 with partial remission (subthereshold), and scores of 5 to 7 with episode. The PSR was linked with an ICD-10 symptom checklist 30 so that symptomatic state could be matched with the ICD-10 episode status. The term partial remission used at discharge was replaced during follow-up by the term subthreshold because of the diffi culty of deciding whether a patient is remitting from an episode or actually in a relapse process.
Using the monthly PSR ratings, the percentage of time patients spent in each prespecifi ed clinical state (remission, subthreshold, and episode) was computed, this, in turn, allowing specifi cation of the occurrence of the primary outcome (a poor outcome, compared with a good outcome).
Relapse was assessed in patients who entered partial or full remission either at the end of treatment or during the follow-up period. Relapse was defi ned as the return of an ICD-10 depressive episode (that is, a PSR of 5, 6, or 7) lasting for at least 1 month, after an episode-free period of 1 month or longer.
Data Management. SPSS Version 15 (SPSS Inc, Chicago, IL) was used for data entry and analysis. As per the hypothesis, data were stratifi ed according to discharge status for the main analysis.
Three main analytic strategies were followed: for simple comparisons of 2 independent groups, independent samples t test or Mann-Whitney U test were used; for comparison of multiple groups, ANOVA or Kruskal-Wallis tests were used. Pearson chi-square tests were used for categorical data; for the analysis of the main summary outcomes weeks, IQR = 26 weeks) than nonparticipants (median 9.5 weeks, IQR = 21) (P = 0.007).
Among the 118 patients, 40 (34%) were discharged in clinical remission, 36 (31%) in partial remission, and 42 (37%) in episode. Most patients were women (75%), married or cohabiting (56%), unemployed (68%), or retired (14%). The median duration of the index depressive episode was 3.0 years (IQR = 7) while the mean (SD) total duration of illness was 18.9 years (14.1). Patients were followed-up for a median of 37.5 (IQR = 37.2) months, with a minimum of 8 months and a maximum of 84 months. Five patients were followed-up for just under a year (1 for 8 months, 2 for 10 months, and another 2 for 11 months). Removing these 5 from the data has only a marginal impact on duration of follow-up.
Clinical Outcome
Primary Outcome: Longitudinal Course. During followup, the mean (SD) percentage of time patients spent in remission, subthreshold state, and episode was 36% (39.3%), 39% (39.2%), and 25% (33.8%), respectively. The percentage of time spent in different clinical states was signifi cantly different among the groups stratifi ed according to discharge status as shown in Figure 1 . Figure  1 depicts the mean percentage of time spent in various clinical states. Thus patients discharged in remission spent signifi cantly more follow-up time in remission (mean 79%, SD 24.8%, compared with patients discharged in partial remission (mean 19%, SD 26.2%) and in episode (mean 16%, SD 28.2%). Similarly, patients discharged in episode spent most of their follow-up time in episode, while patients (good and poor outcome) we used the logistic regression model to quantify the independent effect of discharge status on these outcomes. As our hypothesis was focused on discharge status, different potential confounding variables were progressively added into the initial model in which only discharge status was fi tted. Discharge status was either entered as continuous variables based on the PSR scores (that is, scores of 1 to 7) or as categories using dummy variables, depending on the analysis.
Finally, we were also interested in patients who remained in episode at the end of treatment, but who later attained partial or full remission during follow-up. We compared this subgroup with patients who remained in a persistent depressive episode, and those who had already reached partial or full remission by the end of treatment.
Results
Baseline Sociodemographic and Clinical Characteristics
Among the 150 patients with TRD who had received treatment and were approached for our study, 118 (78.7%) were successfully followed-up. Reasons for nonparticipation in the study were as follows: 7 refused to take part, 8 were not traced because of change of address, 13 were deceased, and 4 were excluded because of incomplete data. There was no signifi cant difference in any of the baseline characteristics, including illness severity, between participants and nonparticipants, except for duration of inpatient treatment. This was signifi cantly longer for participants (median 24.0 discharged in partial remission spent most of their follow-up time in a subthreshold state ( Figure 1 ). Cumulatively, 81% of participants achieved either remission or partial remission at least once; however, the proportion achieving full remission at any given follow-up time was never above 40%.
Cross-Sectional Outcome. In cross-sectional assessment, the PSR scores mirrored the longitudinal fi ndings. For the month of the fi nal follow-up assessment: most patients discharged in episode were found to be in episode; most patients discharged in partial remission were in subthreshold state; and most patients discharged in remission were in remission ( Figure 2 ). The assessments on other scales (HDRS and QIDS-C) also confi rmed these differential outcomes ( Table 2 and Figure 3 ).
Relapse.
Although there was no signifi cant difference between the various discharge groups, the proportion relapsing (that is, showing recurrence of a full episode for at least 1 month) was lowest for patients who were discharged in full remission (48%; n = 19). Relapse rates were higher for patients discharged in partial remission (64%; n = 23). Among those discharged still in episode but who entered remission during follow-up, 53% (n = 10) subsequently relapsed. Patients who had been discharged in remission but who then relapsed experienced a shorter relapse episode (median 3.0; IQR = 4 months) than patients who had been discharged in partial remission (median 4.0; IQR = 8) and those who had only entered remission postdischarge (median 5.5; IQR = 13.5). The time to relapse was not statistically signifi cantly different between the groups (log rank χ 2 = 0.436, df = 2, P = 1.66), although patients discharged in remission remained well for a numerically longer period before relapse (median 18.5 months, IQR = 25.5), compared with patients discharged in partial remission (median 14.0 months, IQR = 31.5) and patients discharged in episode but who attained remission postdischarge (median 12.0 months, IQR = 23).
Functional Outcome. Details are presented in Table 2 and Figure 3 . The mean GAF score overall was 68.2 (SD 16.3) and signifi cantly higher for patients discharged in remission, compared with patients discharged in partial remission (P = 0.04) and those discharged in episode (P < 0.001). Patients discharged in partial remission also had better functioning than those discharged in episode (P = 0.002). Postdischarge Recovery. Patients who recovered symptomatically, attaining either partial or full remission at any point during follow-up (n = 19) after being discharged in episode (n = 42), had comparably good clinical and functional outcome at follow-up as patients discharged already symptomatically improved (in partial or full remission). This difference is more apparent when the postdischarge recovery group are compared with those with persistent illness: the mean GAF score for pateints with persistent illness was 45.6 (SD 13.0), while for patients who recovered postdischarge it was 71.7 (SD 14.1). This difference was highly signifi cant (mean difference -26.1; 95% CI -34.9 to -17.3; P < 0.001). Similarly there were signifi cant differences between the 2 postdischarge groups clinical illness severity as measured using the HDRS and the QIDS. Compared with patients discharged in partial or full remission, patients discharged in episode but subsequently attained postdischarge recovery showed no statistically signifi cant difference in any of the outcome domains.
Prediction of Outcome. Discharge PSR score consistently predicted outcomes (good, compared with poor, outcome) as depicted in Table 3 . For poor outcome-defi ned as longer time in episode and shorter time in remission-a unit increase in the discharge PSR score was associated with a 3-fold increase in the likelihood of poor outcome (AOR 3.11; 95% CI 1.91 to 5.07) ( Table 3) . Good outcome was predicted similarly, with minimal change with adjustment for confounders: a unit decrease in the discharge PSR was associated with a near 3-fold increase in the chance of good outcome (AOR 2.74; 95% CI 1.74 to 4.37). Neither life events nor social support confounded prediction of good outcome.
Discussion
The fi rst main fi nding to emerge from our study is that even in TRD, treating to full remission offers patients the prospect of a better longer-term outcome in several domains. In the longitudinal clinical domain, patients treated to remission spent signifi cantly less time in episode and more time in remission. In terms of cross-sectional symptom severity, patients discharged in remission had signifi cantly less severe illness at the end of the follow-up period. This was also shown in the functional domain, in which patients discharged in remission had signifi cantly better functional outcomes, both self-rated and measured by clinicians.
The second main fi nding is that, while overall, patients discharged still in episode have the worst longer-term outcome, even among patients discharged in episode, a degree of recovery can be attained in nearly 50% of cases. Such postdischarge recovery was associated with comparable clinical and functional outcome with patients who attained predischarge partial or full remission.
A third fi nding is that, as expected, the worst functional outcomes are found in patients who remain in a persistent depressive episode, with no periods of full or partial recovery (20%; n = 23). Follow-up outcome measures were worse in this persistently unwell group than patients who showed a full or partial response to specialist treatment, and worse than for patients who showed postdischarge recovery.
At least 3 main conclusions may be drawn from these fi ndings for clinicians treating patients with TRD. First, the PSR discharge clinical states are a useful guide for projecting the longer-term outcome of the disorder, and thus may be of clinical use. Second, even among patients who are discharged still in episode after treatment in a specialist unit, a reasonable proportion (almost one-half) continue to recover and, following recovery, attain better longer-term outcome trajectories, comparable with patients discharged in remission and partial remission. Finally, full remission is a potentially achievable goal in TRD: the proportion in remission at the time of follow-up was about 70%, 50%, and 30% of patients discharged in remission, partial remission, and episode, respectively.
Our study also confi rms that full remission may be the best goal of intervention in TRD. Patients discharged in full remission had a clear advantage over those discharged in partial remission in most domains of clinical and functional outcome ( Table 2 and Figure 3 ). Although not reaching statistical signifi cance, a much higher proportion of patients discharged in partial remission (64%) went on to relapse, compared with patients discharged in full remission (48%). There was also a trend for delayed relapse and shorter duration of subsequent episodes in relapse in patients discharged in full remission. Given the small sample size in each subgroup, our study was not adequately powered to detect signifi cant difference in these relapse rates, despite the reasonably large size of the difference. At least in the short-term, studies on the outcome of depression have demonstrated increased risk of relapse among patients treated only to partial remission. [31] [32] [33] Full remission was also associated with better functioning at follow-up.
Although we anticipate little disagreement that full remission has to be the goal of treatment, even in TRD, it is legitimate to ask whether this is actually achievable. In a limited way, our study suggests that a degree of recovery is achievable, even among people who failed to show expected recovery following intensive treatment in a specialist unit. By the end of the follow-up (at a median of 3 years), 81 people (69%) had achieved either remission or partial remission at some point in time. Conversely, the proportion exhibiting full remission at any one follow-up point was under 40%. However, our data suggests that even when it is diffi cult to achieve the desired goal of full remission, recovering to a subthreshold level is crucial in improving the longer-term prospect of patients in terms of symptoms and function. Thus failing short of the desired goal of full remission, the second best treatment target appears to be interrupting the persistence of depressive episode, even if signifi cant residual symptomatology remains.
Functional recovery is an important aspect of the recovery process. It has been suggested as an important end point in trials of AD treatments. 17, 34 Functioning is a complex process affected not only by illness factors but also other individual and environmental factors. Although clearly linked with clinical outcome among this cohort, a functional scale that takes into account the complex nature of functional outcome is necessary before it can be recommended as a primary treatment end point.
Our study was conducted in a tertiary specialist centre where patients with more severe illness and complex treatment needs are seen. This may introduce selection bias and may limit generalizability. However, our fi ndings are in line with the recommendations and fi ndings of research into depression in general. Studies in depression have described the impact of residual symptoms on outcome 17, 35 and have proposed full remission as the optimal target for the treatment of depression. 8, 17, 35 The variable and the long follow-up interval may also be another source of limitation. The LIFE chart is designed, with its provisions for anchoring dates and events to the course of the illness, for longer-term interval assessments. We have also attempted to account for the differential impact of the variable length of follow-up either by adjusting for its effect in the analysis or by looking at different follow-up interval gaps separately. To further limit recall bias, we have attempted to use all sources of information, including informants and records. All assessments of functioning were conducted at the end of follow-up and thus it was not possible to determine the longitudinal course of functional impairment. Another limitation might also be that we do not account for any reduction in severity of episode. Reduction in episode severity (for example, from severe to moderate or mild depression) might also be a valuable outcome, although the study had insuffi cient power to examine this. Finally, we acknowledge that this is a naturalistic study and that other uncontrolled factors may be affecting patient outcome.
To our knowledge, this is the fi rst systematic study to look at a well-characterized cohort of patients with TRD to determine the longer-term outcome as a function of baseline, end of treatment clinical status. We conclude that full remission is a desired goal of treatment, even in TRD, and one that is achievable in a substantial proportion. However, partial remission with ongoing residual symptoms still confers an improved long-term symptomatic and functional outcome, and should represent the minimum achievable target for treatment in TRD.
